Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-blinded, Active-control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34+ Cells (Auto-CD34+ Cells) for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia

Next Previous
Trial Profile

A Prospective, Randomized, Double-blinded, Active-control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34+ Cells (Auto-CD34+ Cells) for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CLBS-14 (Primary)
  • Indications Angina pectoris; Myocardial ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms RENEW
  • Sponsors Baxalta; Baxter Healthcare Corporation; Caladrius Biosciences

Most Recent Events

  • 11 Dec 2015 Status changed from active, no longer recruiting to completed according to to ClinicalTrials.gov record.
  • 22 May 2015 Planned End Date changed from 1 Jun 2016 to 1 Nov 2015, according to to ClinicalTrials.gov record.
  • 22 May 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2015, according to to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top